RNAZ · XBRL financial data

Transcode Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (RNAZ's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q3 FY23Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Research and development	3,343	3,364*	1,759	3,082	1,227	3,638*	2,220	2,566	3,161	5,475*	5,107	3,694
General and administrative	1,985	695*	1,530	2,032	938	1,454*	952	1,655	1,400	1,764*	2,222	2,536
Total operating expenses	5,328	4,059*	3,289	5,114	2,165	5,092*	3,171	4,221	4,561	16,027*	17,755	6,790
Operating income (loss)	(5,328)	(4,059)*	(3,289)	(5,114)	(2,165)	(5,092)*	(3,171)	(4,221)	(4,561)	(16,027)*	(17,755)	(6,790)
Interest income	0	0*	0	0	0	0*	0	0	0	79*	92	52
Interest expense	17	17*	10	4	11	2*	0	0*	6	1*	—	—
Income tax expense (benefit)	0	0*	0	0	0	0*	0	0*	0*	226*	—	—
Net income (loss)	(5,300)	(4,088)*	(3,327)	(5,191)	(2,321)	(5,916)*	(12,085)	(4,277)	(4,856)	(13,443)*	(17,785)	(6,750)
Earnings per share, basic‡ USD per share	(62,745.10)	—	(24,276.38)	(27,637.72)	(5,975.72)	—	(70.31)	(5.13)	(5.82)	—	(21.28)	(7.17)
Earnings per share, diluted‡ USD per share	(62,745.10)	—	(24,276.38)	(27,637.72)	(5,975.72)	—	(70.31)	(5.13)	(5.82)	—	(21.28)	(7.17)
Weighted average shares, basic‡ thousands of shares	0	—	0	0	0	—	172	834	834	—	917	957
Weighted average shares, diluted‡ thousands of shares	0	—	0	0	0	—	172	834	834	—	917	957

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (December 2023); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-40 stock split (January 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-33.333333333333336 stock split (December 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-28.011204481792713 stock split (May 2025); filings made before it reported them unadjusted.
† Share count changed about 1804x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 18x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (RNAZ's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q3 FY23Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Cash and cash equivalents	7,453	2,768	4,914	3,355	1,876	5,811	11,569	7,375	2,836	17,814	12,835	8,383
Prepaid and other current assets	1,920	1,688	1,800	1,032	1,725	1,282	1,153	691	1,717	919	1,615	2,259
Total current assets	9,373	4,455	6,714	4,386	3,613	7,093	13,044	8,242	4,751	21,984	16,749	10,643
Property and equipment, net	152	121	92	65	61	52	38	25	20	371	347	323
Right-of-use asset	590	482	372	262	150	38	—	—	—	—	—	—
Goodwill	—	—	—	—	—	—	—	—	—	25,744	25,744	25,744
Total assets	10,228	5,170	7,290	4,825	3,936	7,294	13,194	8,266	5,227	162,399	157,165	151,010
Total current liabilities	5,598	3,491	2,706	3,502	2,284	2,772	2,510	1,565	2,968	3,494	5,379	5,399
Lease liability, non-current	190	38	—	—	—	—	—	—	—	—	—	—
Total liabilities	5,788	3,529	2,706	3,502	2,284	9,313	2,902	2,119	3,801	10,519	12,644	12,652
Accumulated deficit	(42,329)	(46,416)	(49,743)	(54,934)	(57,255)	(63,202)	(75,287)	(79,564)	(84,420)	(97,863)	(115,648)	(122,398)
Total stockholders' equity	4,440	1,641	4,584	1,322	1,652	(2,019)	10,293	6,148	1,426	10,335	1,251	(27,695)
Total liabilities and equity	10,228	5,170	7,290	4,825	3,936	7,294	13,194	8,266	5,227	162,399	157,165	151,010
Common shares outstanding (cover page)‡ thousands of shares	1	0	0	0	0	833	833	834	917	917	950	16,931

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (December 2023); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-40 stock split (January 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-33.333333333333336 stock split (December 2024); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 1-for-28.011204481792713 stock split (May 2025); filings made before it reported them unadjusted.
† Share count changed about 1804x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 18x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (RNAZ's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q3 FY23Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Net income (loss)	(5,300)	(4,088)*	(3,327)	(5,191)	(2,321)	(5,916)*	(12,085)	(4,277)	(4,856)	(13,443)*	(17,785)	(6,750)
Stock-based compensation	392*	310*	183	1,144*	204*	169*	158	132*	134*	62*	—	—
Depreciation and amortization	31	32*	32	32	16	10*	13	13	5	45*	24	24
Net cash from operating activities	(3,506)*	(5,663)*	(3,937)	(2,340)*	(3,913)*	(3,146)*	(3,097)	(4,194)*	(4,083)*	(8,142)*	(4,978)	(5,402)*
Purchases of property and equipment	5*	0*	4	5*	13*	1*	—	—	—	year only	—	—
Net cash from investing activities	(5)*	0*	(4)	(5)*	(13)*	(1)*	—	—	—	year only	—	—
Proceeds from issuing common stock	7,255*	978*	6,087	785*	2,447*	7,082*	8,855	0*	0*	0*	—	—
Net cash from financing activities	7,391*	978*	6,087	785*	2,447*	7,082*	8,855	0*	(456)*	23,124*	—	—
Net change in cash	3,880*	(4,685)*	2,146	(1,559)*	(1,479)*	3,935*	5,758	(4,194)*	(4,539)*	14,978*	(4,978)	(4,452)*

† Share count changed about 1804x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 18x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Transcode Therapeutics	8,383	not reported	(5,402)*	16.9M	1.6 quarters	Q2 FY26 10-QJun 30, 2026
Adial Pharmaceuticals	28,712	not reported	(6,363)*	2.6M	4.5 quarters	Q2 FY26 10-Q/AJun 30, 2026
AIM ImmunoTech	9,900	26	(4,590)*	30.4M	2.2 quarters	Q2 FY26 10-QJun 30, 2026
Vyome Holdings	7,888	27	(904)*	7.0M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
Biomerica	2,733	1,265	(802)	4.6M	3.4 quarters	Q1 FY27 10-QAug 31, 2026
Protagenic Therapeutics, Inc.\new	566	not reported	(944)	1.8M	0.6 quarters	Q1 FY26 10-QJun 30, 2026
PharmaCyte Biotech	17,739	0	(781)	10.7M	22.8 quarters	Q1 FY27 10-QJul 31, 2026
Natural Alternatives International	7,388	not reported	(1,066)*	22.1M	6.9 quarters	Q4 FY26 10-KJun 30, 2026
LFTD Partners	1,504	8,705	(555)*	14.8M	2.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.